Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study

Alex Walker1 | Lars Erwig1 | Katie Foster1 | Katherine Nevin1 | Joerg Wenzel2 | Margitta Worm3 | Nicola Williams1 | Nirav Ratia1 | Bao Hoang4 | Tanja Schneider-Merck5 | Sophie Gisbert6 | Heike Carnarius5 | Marion Dickson1

1GSK, Stevenage, UK
2University Hospital of Bonn, Bonn, Germany
3Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité, Berlin, Germany
4GSK, Collegeville, PA, USA
5GSK, Hamburg, Germany
6GSK, Uxbridge, UK

Abstract
The immunoregulator spleen tyrosine kinase (SYK) is upregulated in cutaneous lupus erythematosus (CLE). This double-blind, multicentre, Phase Ib study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of the selective SYK inhibitor GSK2646264 in active CLE lesions. Two lesions from each participant (n = 11) were each randomized to topical application of 1% (w/w) GSK2646264 or placebo for 28 days; all participants received GSK2646264 and placebo. The primary endpoint was safety and tolerability of GSK2646264, assessed by adverse event incidence and a skin tolerability test. Secondary endpoints included change from baseline in clinical activity and mRNA expression of interferon-related genes in skin biopsies. Levels of several immune cell markers were evaluated over time. Eight (73%) participants experienced ≥ 1 adverse event (all mild in intensity), and maximal dermal response was similar for GSK2646264 and placebo. The expression of several interferon-related genes, including CXCL10 and OAS1, showed modest decreases from baseline after 28 days of treatment with GSK2646264 compared with placebo. Similar findings were observed for CD3+ T cell and CD11c+ dendritic cell levels; however, overall clinical activity remained unchanged with GSK2646264 vs. placebo. Further studies are warranted to assess SYK inhibitors as potential treatment for CLE.

KEYWORDS
cutaneous lupus erythematosus, interferons, pharmacology, safety, SYK Kinase
1 | BACKGROUND

Cutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune skin disease with several subtypes, including acute, subacute and chronic.1,2 Studies have demonstrated a substantial burden from CLE on healthcare systems and patient lives, highlighting an unmet treatment need.3–5 Consistent with this, patients have expressed a desire for disease-modifying therapies that alleviate CLE symptoms and allow them to reduce the number of pills taken.3

Inflammation associated with cutaneous lupus lesions is likely driven through activation of the interferon (IFN) pathway and potentially mediated by spleen tyrosine kinase (SYK), suggesting that SYK is a putative target for treating CLE (Appendix S1).6,7 The novel small molecule SYK inhibitor GSK2646264 has good potency, selectivity and skin permeability8 and has recently shown encouraging preclinical results as a topical treatment for skin mast cell diseases.9

2 | QUESTIONS ADDRESSED

This study examined the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of repeat topical applications of GSK2646264 vs. placebo in participants with CLE lesions.

3 | EXPERIMENTAL DESIGN

This double-blind (sponsor-unblinded) Phase Ib (GSK study number: 204860; ClinicalTrials.gov: NCT02927457) study was conducted across five centres in Germany between 13 January 2017 and 12 June 2018. Eleven participants with ≥2 active lesions were randomized into the “active lesion cohort” (6 chronic CLE, 5 subacute CLE) (Figure S1). A separate enrolment to a “photoprovocation cohort” was planned for participants with 0 or 1 active lesions to study the effect of GSK2646264 on photoprovocation-induced, non-scared, non-chronic lesions; however, no participants were randomized to this cohort due to feasibility of recruitment (Appendix S2). This report focuses on the active lesion cohort only.

Key inclusion criteria included were as follows: 18–70 years of age; histologically confirmed subacute or chronic CLE; free from scarring, skin markings or wounds in the areas to be treated; and no extended direct sunlight and tanning products on the areas to be treated. The use of prednisolone > 7.5 mg daily and hydroxychloroquine > 400 mg daily was prohibited. See Appendix S3 for full eligibility criteria.

Two active lesions from the same anatomical area per participant were each randomized to GSK2646264, administered topically once daily as a 1% (w/w) strength cream or placebo, both with identical excipients for a period of 28 days; all participants received GSK2646264 and placebo. Both GSK2646264 and placebo were formulated as a white/off-white aqueous cream, manufactured by Medpharm Guildford and stored in amber glass jars at 2–8°C. The maximum applied GSK2646264 dose at any time point was 10 mg/cm² over 90 cm² (900 mg cream containing GSK2646264 9 mg). One participant received placebo and GSK2646264 at the same lesion and was excluded from biomarker, mRNA and efficacy analyses.

The primary endpoint was the safety of GSK2646264 (incidence of adverse events [AEs] and serious AEs [SAEs], clinical safety

---

**TABLE 1** Participant demographics and baseline characteristics

| Characteristic | Total (N = 11) |
|----------------|--------------|
| Female, n (%)  | 9 (82)       |
| Age (years)    |              |
| Mean (SD)      | 54.8 (10.44) |
| Median (range) | 53 (39–68)   |
| BMI (kg/m²), mean (SD) | 23.9 (3.09) |
| Height (cm), mean (SD) | 165.8 (8.42) |
| Weight (kg), mean (SD) | 65.5 (9.63) |
| Race, n (%)    |              |
| African American/African | 1 (9) |
| White/Caucasian/European | 10 (91) |
| CLE type, n (%)|              |
| Chronic        | 6 (55)       |
| Acute          | 0            |
| Subacute       | 5 (45)       |
| Concomitant medication a, n (%) b|              |
| Any            | 10 (91)      |
| Hydroxychloroquine sulphate | 9 (82) |
| Prednisolone   | 5 (45)       |
| Cholecalciferol| 3 (27)       |
| Metamizole sodium | 3 (27)       |

Abbreviations: BMI, body mass index; CLE, chronic lupus erythematosus; SD, standard deviation.

*Eligible participants were stable on either no treatment or treatment with: corticosteroids (≤7.5 mg/day prednisone or prednisone equivalent or less) for a minimum of 30 days prior to screening and through to Day 28; hydroxychloroquine (≤400 mg daily dose) for a minimum of 60 days prior to the randomization visit through to Day 28; topical steroids applied to areas of the body that are not exposed to GSK2646264 from screening to Day 28; topical calcineurin inhibitors and retinoids applied to areas of the body that are not exposed to GSK2646264 from screening to Day 28; opioids, if required for acute and chronic pain management.

*Only medications being taken by three or more participants are shown.

---

**FIGURE 1** Adjusted mean (95% CI) intensity of log2 mRNA expression by visit and treatment (A) CXCL10, (B) IFI44, (C) IFIH1, (D) OAS1, (E) IL1A, (F) IL1B, and (G) IL6, (H) IFI16, (I) IFI44L, (J) IFIT1 and (K) IFIT3. For genes that had more than one probe analysed, the probe that showed the largest treatment difference is shown. Adjusted mean intensity values were derived using a mixed model with participant as a random effect and treatment as a fixed effect where treatment is set to “not applicable” at baseline. CI, confidence interval.
1688 | WALKER ET AL.

(A) CXCL10

(B) IFI44

(C) IFIH1

(D) OAS1

(E) IL1A

(F) IL1B

(G) IL6

(H) IFI16

(I) IFI44L

(J) IFIT1

(K) IFIT3

Baseline | Visit | Day 28

Adjusted mean ± 95% CI

Baseline | Visit | Day 28

Treatment:
Placebo (N = 10)
GSK2646264 (N = 10)
Treatment: Placebo (N = 10) – GSK2646264 (N = 10)

(A) CD3+ T lymphocytes
CLE type: chronic
Baseline Visit Day 28
Mean ± SE

CLE type: sub-acute
Baseline Visit Day 28
Mean ± SE

CLE type: all
Baseline Visit Day 28
Mean ± SE

(B) CD11c+ dendritic cells
CLE type: chronic
Baseline Visit Day 28
Mean ± SE

CLE type: sub-acute
Baseline Visit Day 28
Mean ± SE

CLE type: all
Baseline Visit Day 28
Mean ± SE

Participant #8

i
ii
iii
iv
v
vi
vii
viii
ix
x

CD3
CD11c

Participant #9

xi
xii
xiii
xiv
xv
xvi
xvii
xviii
ixx
xx

CD3
CD11c

Uninvolved Baseline placebo Baseline GSK2646264 Day 28 placebo Day 28 GSK2646264
FIGURE 2 Mean (±SE) expression (cells/mm²) of (A) CD3 + T cells and (B) CD11c + dendritic cells in the dermis from biopsies by visit, treatment and sub-acute/chronic CLE subtypes. Immunohistochemical staining (C) of CD3 + T cells (i–v, xi–xvi) and CD11c + dendritic cells (vi–x, xvi–xx) in CLE skin samples in the presence and absence of GSK2646264 treatment from two representative participants. Images represent uninvolved (i, vi, xi, xvi), baseline placebo (ii, vii, xii, xvii), baseline GSK2646264 (iii, viii, xiii, xviii), placebo-treated at Day 28 (iv, ix, ixv, ixvii) and GSK2646264-treated (x, v, xv, xx) at Day 28. Yellow staining = CD3/CD11c; blue staining = haematoxylin; green = overlap of yellow and blue staining. Scale bars denote 200 μm. Images from Participant #8 and Participant #9 are included as representative images for participants in which immunohistochemical staining changes were and were not observed, respectively. CLE, chronic lupus erythematosus; SE, standard error.
A small reduction from baseline in CD3+ T cells and CD11c+ dendritic cells in the dermis was observed with GSK2646264 vs. placebo on Day 28 for participants with chronic, but not subacute CLE (Figure 2A, B). These findings are consistent with a previous study, which reported reductions of CD11c+ dendritic cells from the skin of MRL-lpr mice with the SYK inhibitor R788. This may be explained by the involvement of CD3+ T cells and CD11c+ dendritic cells in the development of the interface dermatitis at the dermal/epidermal junctional lesions in chronic CLE via production of IFN-α and IFN-β. Representative immunohistochemistry images of CD3+ T cell and CD11c+ dendritic cell staining from two participants with chronic CLE are shown in Figure 2C.

No changes from baseline in the expression of CD68, CD20 or CD123 were observed in either CLE subtype. Similarly, no changes were observed in expression of pSYK or total SYK; however, assaying phosphoprotein levels within tissue biopsies is challenging due to the dynamic nature of protein phosphorylation and the invasive nature of biopsy.

4.5.3 | Histopathology score

No differences were observed between GSK2646264- and placebo-treated lesions in overall histopathology score (Figure S5A) or any of its components. For the dermal inflammation component, there was a modest reduction from baseline to Day 28 with GSK2646264 vs. placebo for the chronic CLE subgroup, but not the subacute subgroup (Figure S5B).

5 | CONCLUSIONS AND PERSPECTIVES

Topical application of the SYK inhibitor GSK2646264 to active chronic and subacute CLE lesions was well tolerated over 28 days of treatment and no new safety concerns were identified. There was no difference between GSK2646264 and placebo groups in change from baseline in RCLASI, nor in expression of pSYK or total SYK. However, small reductions in the expression of several IFN- and inflammatory-induced genes were observed with GSK2646264 vs. placebo. In participants with chronic CLE, there was a modest reduction in dermal inflammation and levels of CD3+ T cells and CD11c+ dendritic cells in the dermis with GSK2646264 vs. placebo.

A key limitation of this study is the small sample size resulting from lower than intended recruitment levels, which precluded a formal statistical analysis of several endpoints; these data should therefore be interpreted with caution.

In conclusion, these putative reductions in the expression of IFN pathway and other inflammatory-related genes and in dermal inflammation following GSK2646264 treatment in participants with chronic CLE indicate that further studies assessing the efficacy and safety of SYK inhibitors in CLE are warranted.

ACKNOWLEDGEMENTS

The authors would like to thank Professor Annegret Kuhn for her input to the study design, Dr Silke Hoffmann, Dr Nina Magnolo and Professor Kamran Ghoreschi, who contributed to recruitment, Amy-Beth Travis for data management support and Rejbinder Kaur for operational support. This study was funded by GlaxoSmithKline (GSK study number: 204860; ClinicalTrials.gov: NCT02927457). Medical writing support (in the form of writing assistance, including development of the initial draft based on author direction, assembling tables and figures, collating authors’ comments, grammatical editing and referencing) was provided by Liam Campbell, PhD, and Clare Slater, PhD, at Fishawack Indicia Ltd, UK, funded by GSK.

CONFLICT OF INTEREST

AW, KF, KN, NW, NR, BH, TSM, SG and HC are employees of GSK and hold stocks/shares in GSK. LE and MD were employees of GSK at the time of the study. JW reports grants from GSK, grants from Incyte, personal fees from Biogen, personal fees from Leo Pharma and other from Novartis. MW reports honoraria for consulting by ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Bencard Allergie GmbH, Novartis AG, Biotest AG, Actelion Pharmaceuticals Deutschland GmbH, Sanofi-Aventis Deutschland GmbH and HAL Allergie GmbH.

AUTHOR CONTRIBUTIONS

AW, LE, KF, KN, JW, MW, NW, NR, BH, TSM, SG, HC and MD contributed to the conception or design of the study. JW and MW were involved in the acquisition of the study data. AW, MD, NR, SG and BH contributed to the analysis and interpretation of the data. All authors have read and approved the final manuscript.

ETHICAL APPROVAL

This study was reviewed and approved by local research ethics committees prior to commencement. The study was conducted in accordance with International Council on Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice ethical principles and the Declaration of Helsinki. Written informed consent was obtained from each participant prior to study commencement.
REFERENCES

1. Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27:391-404. https://doi.org/10.1016/j.berh.2013.07.008

2. Presto JK, Hejazi EZ, Werth VP. Biological therapies in the treatment of cutaneous lupus erythematosus. Lupus. 2017;26:115-118. https://doi.org/10.1177/0961203316670731

3. Ogunsanya ME, Brown CM, Lin D, Imarhia F, Maxey C, Chong BF. Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. Int J Womens Dermatol. 2018;4:152-158. https://doi.org/10.1016/j.ijiwd.2018.01.002

4. Hall SA, Chen SY, Kao A, et al. 162 Symptom impact and unmet need in systemic/cutaneous lupus erythematosus: results from a patient-centred study set in a social media community. Lupus Sci Med. 2017;4:A77. https://doi.org/10.1136/lupus-2017-000215.162

5. Werth V, Eldar-Lissai A, Ning W. 155 Disease burden and healthcare resource utilisation among cutaneous lupus erythematosus patients with depression and/or anxiety; quantifying the unmet need. Lupus Sci Med. 2017;4:A71. https://doi.org/10.1136/lupus-2017-000215.155

6. Braegelmann C, Holzel M, Ludbrook V, et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp Dermatol. 2016;25:375-379. https://doi.org/10.1111/exd.12986

7. Mocsai A, Ruland J, Tybulewicz VLI. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10:387-402. https://doi.org/10.1038/nri2765

8. Barker MD, Liddle J, Atkinson FL, et al. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett. 2018;28:3458-3462. https://doi.org/10.1016/j.bmcl.2018.09.022

9. Ramirez Molina C, Falkencrone S, Skov PS, Hooper-Greenhill E, Barker M, Dickson MC. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. Br J Pharmacol. 2019;176:1135-1142. https://doi.org/10.1111/bph.14610

10. Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163:83-92. https://doi.org/10.1111/j.1365-2133.2010.09799.x

11. Li H, Ice JA, Lessard CJ, Sivils KL. Interferons in Sjögren's syndrome: genes, mechanisms, and effects. Front Immunol. 2013;4:290. https://doi.org/10.3389/fimmu.2013.00290

12. Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated genes signature in systemic lupus erythematosus and discoid lupus erythematosus. Br J Dermatol. 2012;166:71-75. https://doi.org/10.1111/j.1365-2133.2012.10656.x

13. Chuang JY, Huang YL, Yen WL, Chiang IP, Tsai MH, Tang CH. Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int J Mol Sci. 2014;15:545-559. https://doi.org/10.3390/ijms15010545

14. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010;62:2086-2092. https://doi.org/10.1002/art.27452

15. Guiducci C, Tripodo C, Gong M, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med. 2010;207:2931-2942. https://doi.org/10.1084/jem.20101048

16. Hussein MR, Abouhagag NM, Atta HS, Atta SM. Evaluation of the profile of the immune cell infiltrate in lichen planus, discoid lupus erythematosus, and chronic dermatitis. Pathology. 2008;40:682-693. https://doi.org/10.1080/00313950802320739

17. Chen IH, Xue L, Hsu CC, et al. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci USA. 2017;114:3175-3180. https://doi.org/10.1073/pnas.1618088114

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

Appendix S1. Background

Appendix S2. Photoprovocation cohort summary

Appendix S3. Supplementary methods

Appendix S4. Supplementary results: Safety and tolerability

Figure S1. Participant disposition

Figure S2. Mean (±SE) (A) overall and (B) modified RCLASI activity scores by visit, treatment and sub-acute/chronic CLE subtypes

Figure S3. Median (range) GSK2646264 plasma concentrations throughout the study

Figure S4. Heatmap of log2 mRNA expression levels for gene probes of interest for individual participants at each visit and treatment, shown by sub-acute and chronic CLE subtypes

Figure S5. Mean (±SE) (A) overall histopathology score and (B) histopathology score for the dermal inflammation component by visit, treatment and sub-acute/chronic CLE subtypes

How to cite this article: Walker A, Erwig L, Foster K, et al. Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase I b study. Exp Dermatol. 2021;30:1686-1692. https://doi.org/10.1111/exd.14253

DATA SHARING STATEMENT

Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

ORCID

Alex Walker https://orcid.org/0000-0001-9934-4150